Superworth

Syndax Pharmaceuticals SNDX

Drug Manufacturers - General, Healthcare
$13.10
−4.03%
Market cap
$1.2B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
4.6×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$289.7M
+160% on a year ago
Net margin
−87.5%
Free cash flow yield
n/m
not a meaningful number

Syndax Pharmaceuticals trades at 4.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $289.7M over the last twelve months, up 160% on a year earlier with a −88% net margin.

Charts

Financials

Income statement for SNDX, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$0$0$3.5M$12.5M$7.7M$20M$38M+985%$45.9M+267%$68.7M+795%$64.9M+224%$72.8M+92%$83.3M+82%
R&D$55.1M+73%$56.5M+66%$48.7M+40%$71M+82%$65.5M+19%$61.6M+9%$62.2M+28%$56.3M−21%$78.6M+20%$58.8M−5%$68M+9%$67.5M+20%
SG&A$22.8M+124%$23M+93%$29.1M+95%$31.1M+80%$37.7M+66%$41M+78%$43.8M+51%$44.9M+44%$49.9M+33%$37.6M−8%$41.5M−5%$43.7M−3%
−$77.9M+85%−$79.5M+73%−$74.2M+49%−$89.6M+59%−$96.4M+24%−$83.8M+5%−$69.4M−7%−$57.4M−36%−$62.5M−35%−$34.2M−59%−$40M−42%−$41.9M−27%
Interest expense$63K+47%$55K+38%$45K+29%$23K−67%$4.8M+7529%$2K−96%$4K−91%$0$0$0$2K−50%$2K
Net income−$72.5M+85%−$72.4M+76%−$68.1M+53%−$84.1M+65%−$94.2M+30%−$84.8M+17%−$71.8M+6%−$60.7M−28%−$68M−28%−$42.7M−50%−$49.4M−31%−$49.4M−19%
−$1.00+61%−$0.85+44%−$0.80+25%−$0.98+34%−$1.09+9%−$0.98+15%−$0.83+4%−$0.70−29%−$0.78−28%−$0.48−51%−$0.55−34%−$0.55−21%
72.5M+15%85.2M+23%85.3M+23%85.4M+22%86.6M+19%86.2M+1%86.3M+1%86.6M+1%86.9M+0%88.3M+2%89M+3%89.8M+4%

Revenue: Q1 FY15: 6 months less the 3 months printed beside them.

EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q4 FY21: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Syndax Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
SNDXSyndax Pharmaceuticals$1.2Bn/m65.8×4.6×+160%−87.5%
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
Peer median$1.3B13.7×19.8×1.8×+17%10.9%

More on Syndax Pharmaceuticals

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .